Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus?

In this Perspective on the clinical trial by Rita Alloway and colleagues, Simon Ball explains the benefits to healthcare systems and individual patients of the bioequivalence established between generic and brand-name formulations of an immunosuppressive drug in transplant recipients.

Detalles Bibliográficos
Autor principal: Ball, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685474/
https://www.ncbi.nlm.nih.gov/pubmed/29135980
http://dx.doi.org/10.1371/journal.pmed.1002429
Descripción
Sumario:In this Perspective on the clinical trial by Rita Alloway and colleagues, Simon Ball explains the benefits to healthcare systems and individual patients of the bioequivalence established between generic and brand-name formulations of an immunosuppressive drug in transplant recipients.

Ejemplares similares